Manoharan S, Farman T, Piliou S, Mastroeni P
Front Immunol. 2024; 15:1473064.
PMID: 39380985
PMC: 11458423.
DOI: 10.3389/fimmu.2024.1473064.
Gray M, Thomas K, Lamb E, Werner L, Connolly K, Jerse A
Infect Immun. 2023; 91(12):e0030923.
PMID: 37991382
PMC: 10715150.
DOI: 10.1128/iai.00309-23.
Dudek B, Rybka J, Bugla-Ploskonska G, Korzeniowska-Kowal A, Futoma-Koloch B, Pawlak A
Front Microbiol. 2022; 13:1028796.
PMID: 36338080
PMC: 9631793.
DOI: 10.3389/fmicb.2022.1028796.
Shirley M, Taha M
Drugs. 2018; 78(2):257-268.
PMID: 29380290
DOI: 10.1007/s40265-018-0869-7.
Cheng H, Yang Z, Estabrook M, John C, Jarvis G, Mclaughlin S
J Biol Chem. 2011; 286(51):43622-43633.
PMID: 22027827
PMC: 3243514.
DOI: 10.1074/jbc.M111.291583.
Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.
Fransen F, Stenger R, Poelen M, van Dijken H, Kuipers B, Boog C
PLoS One. 2011; 5(12):e15692.
PMID: 21203418
PMC: 3009743.
DOI: 10.1371/journal.pone.0015692.
The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease.
Fransen F, Jan Hamstra H, Boog C, van Putten J, van den Dobbelsteen G, Van der Ley P
Infect Immun. 2010; 78(7):3177-86.
PMID: 20439476
PMC: 2897371.
DOI: 10.1128/IAI.01311-09.
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.
Granoff D, Welsch J, Ram S
Infect Immun. 2008; 77(2):764-9.
PMID: 19047406
PMC: 2632036.
DOI: 10.1128/IAI.01191-08.
Important role for Toll-like receptor 9 in host defense against meningococcal sepsis.
Sjolinder H, Mogensen T, Kilian M, Jonsson A, Paludan S
Infect Immun. 2008; 76(11):5421-8.
PMID: 18794294
PMC: 2573357.
DOI: 10.1128/IAI.00615-08.
Meningococcal vaccines.
Ruggeberg J, Pollard A
Paediatr Drugs. 2004; 6(4):251-66.
PMID: 15339202
DOI: 10.2165/00148581-200406040-00004.
A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
Mountzouros K, Belanger K, Howell A, Bixler Jr G, Madore D
Infect Immun. 2002; 70(12):6576-82.
PMID: 12438327
PMC: 133014.
DOI: 10.1128/IAI.70.12.6576-6582.2002.
Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis.
Coppens I, Alonso S, Antoine R, Jacob-Dubuisson F, Renauld-Mongenie G, Jacobs E
Infect Immun. 2001; 69(9):5440-6.
PMID: 11500415
PMC: 98655.
DOI: 10.1128/IAI.69.9.5440-5446.2001.
High prevalence of complement component C6 deficiency among African-Americans in the south-eastern USA.
Zhu Z, Atkinson T, Hovanky K, Boppana S, Dai Y, Densen P
Clin Exp Immunol. 2000; 119(2):305-10.
PMID: 10632667
PMC: 1905506.
DOI: 10.1046/j.1365-2249.2000.01113.x.
Humoral immune responses to Neisseria meningitidis in children.
Pollard A, Galassini R, van der Voort E, Booy R, LANGFORD P, Nadel S
Infect Immun. 1999; 67(5):2441-51.
PMID: 10225907
PMC: 115990.
DOI: 10.1128/IAI.67.5.2441-2451.1999.
The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.
Kahler C, Martin L, Shih G, Rahman M, Carlson R, Stephens D
Infect Immun. 1998; 66(12):5939-47.
PMID: 9826376
PMC: 108752.
DOI: 10.1128/IAI.66.12.5939-5947.1998.
Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.
Maslanka S, Tappero J, Plikaytis B, Brumberg R, Dykes J, Gheesling L
Infect Immun. 1998; 66(6):2453-9.
PMID: 9596702
PMC: 108224.
DOI: 10.1128/IAI.66.6.2453-2459.1998.
Molecular defects leading to human complement component C6 deficiency in an African-American family.
Zhu Z, Totemchokchyakarn K, Atkinson T, Volanakis J
Clin Exp Immunol. 1998; 111(1):91-6.
PMID: 9472666
PMC: 1904847.
DOI: 10.1046/j.1365-2249.1998.00455.x.
Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose.
Estabrook M, Griffiss J, Jarvis G
Infect Immun. 1997; 65(11):4436-44.
PMID: 9353017
PMC: 175638.
DOI: 10.1128/iai.65.11.4436-4444.1997.
Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.
Maslanka S, Gheesling L, Libutti D, Donaldson K, Harakeh H, Dykes J
Clin Diagn Lab Immunol. 1997; 4(2):156-67.
PMID: 9067649
PMC: 170495.
DOI: 10.1128/cdli.4.2.156-167.1997.
Optimal strategies in immunology III. The IgM-IgG switch.
Perelson A, Goldstein B, Rocklin S
J Math Biol. 1980; 10(3):209-56.
PMID: 7252371
DOI: 10.1007/BF00276984.